What technical signals does LAMEDITECH (462510) have?

LAMEDITECH current technical signals: no active technical signal.

Is LAMEDITECH a cup-and-handle pattern?

No. LAMEDITECH has no valid cup-and-handle signal right now.

What are LAMEDITECH's financials and valuation?

LAMEDITECH's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

LAMEDITECH

462510 · KOSDAQ

₩2,665+2.11%

2026-09-04 close

LAMEDITECH last closed at ₩2,665 (+2.11%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…

No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions

303 picks

Next-day win rate

50.7%

Avg next-day

-0.11%

vs market

-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

EntryAccount sizeStopTarget (optional)Risk per trade (%)

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

Overall: 건강관리 290/291 · top 100%

Factor composite · relative position in sector

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024

Grey zoneFinancial-metric reference signal

Altman Z'' zoneZ'' 2.37

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': 2.37
Beneish M-Score: —
Sloan accrual: 1.44%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

0/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score0/9

Profitability

Positive ROANot passed
Positive OCFNot passed
Improving ΔROANot passed
Accruals (OCF > net income)Not passed

Leverage & liquidity

Lower debtNot passed
Higher current ratioNot passed
No new sharesNot passed

Efficiency

Higher gross marginNot passed
Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -149%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 251 of 287, share 0%.

251 / 2870%revenue share

Who dominates this industry?

1삼성바이오로직스7.3%
2셀트리온5.7%
3녹십자홀딩스3.5%
4유한양행3.3%
5대웅3.1%
6라메디텍0%

Concentration

DistributedCR3 16.6%

HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p: 31.61
Direction: 확대
Level: 넓음
Years: 7

Value lens

P90/P10: 13.9
Median P/B: 1.47
Level: 넓음
n: 263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin: -146.9%
Interest coverage: -161.8x
Return on equity (ROE): -49.5%

Operating margin −5pp

Operating loss

Interest coverageBase -161.8x-167.3x

Return on equity (ROE)Base -49.5%-52.5%

Revenue −15%

Interest coverage risk

Interest coverageBase -161.8x-137.5x

Return on equity (ROE)Base -49.5%-43.2%

Interest rate +2pp

Interest coverage risk

Interest coverageBase -161.8x-78.2x

Return on equity (ROE)Base -49.5%-51.1%

Interest coverage limit

Already below the limit by 147.8pp

Interest coverage limit at an operating margin of 0.9%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-17

Suppliers disclosed by the company in its 2026-03-17 annual report.

Suppliers without disclosed amount

FuhuaElectronicLtdDongGuanNewPrice comovement r=0.15 (1 year)MaterialTechnologyLaserModuleSMT

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

최종석30.72%2026-06-24 · 증감 -1.25%p

Connections

AI-extracted related companies · for reference

Customers

삼성서울병원서울대학교병원

Competitors

씨젠Price comovement r=0.20 (1 year)바디텍메드Price comovement r=0.28 (1 year)에스디바이오센서Price comovement r=0.20 (1 year)휴마시스Price comovement r=0.29 (1 year)메드트로닉 애보트로슈지멘스 헬시니어스벡톤 디킨슨

Same theme

메디톡스Price comovement r=0.30 (1 year)휴온스Price comovement r=0.39 (1 year)인튜이티브 서지컬

🔗 See in the full market map →

Recent filings

LAMEDITECH's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About LAMEDITECH

What technical signals does LAMEDITECH (462510) have?: LAMEDITECH current technical signals: no active technical signal.
Is LAMEDITECH a cup-and-handle pattern?: No. LAMEDITECH has no valid cup-and-handle signal right now.
What are LAMEDITECH's financials and valuation?: LAMEDITECH's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy